© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Nov 22, 2014, the consensus forecast amongst 31 polled investment analysts covering Kalbe Farma Tbk PT advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Nov 14, 2014. The previous consensus forecast advised investors to hold their position in Kalbe Farma Tbk PT.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 18 analysts offering 12 month price targets for
|Div growth (TTM)||-10.53%|
On Jul 25, 2014,
|Average growth rate||+1.48%|
|Average growth rate||+21.12%|
PT Kalbe Farma Tbk had 3rd quarter 2014 revenues of 4.38bn. This missed the 4.47bn estimate of the one analyst following the company. This was 1.52% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+2.56%|
PT Kalbe Farma Tbk had revenues for the full year 2013 of 16.00bn. This was 17.35% above the prior year's results. View Full Annual Financials
|Average growth rate||+15.48%|